SCHEMBL7672173

SCHEMBL7672173

Clc1ccccc1Oc1[c]cccn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.41
HTT P42858 1/20 0.41
SLC6A2 P23975 5/20 0.40
SLC6A4 P31645 4/20 0.40
SLC6A3 Q01959 4/20 0.40
HTR1A P08908 2/20 0.40
LMNA P02545 1/20 0.40
KMT2A Q03164 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
BLM P54132 1/20 0.37
HPGD P15428 1/20 0.37
KCNH2 Q12809 1/20 0.36
SCN5A Q14524 1/20 0.36
SCN9A Q15858 1/20 0.36
MAP4K4 O95819 1/20 0.35
MEN1 O00255 1/20 0.35
CXCL8 P10145 1/20 0.35
ALOX15 P16050 1/20 0.35
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1754861 0.76 P2RY1 (0.45) HTTLMNA
SCHEMBL316115 0.74 LTA4H (0.42) ALDH1A1HTTLMNAKMT2ANPC1
SCHEMBL217907 0.74 RAB9A (0.42) ALDH1A1HTTKMT2ANPC1RAB9A
SCHEMBL1345301 0.71 HPGD (0.41) ALDH1A1HTTSLC6A2SLC6A4SLC6A3
SCHEMBL9499646 0.71 HPGD (0.41) ALDH1A1HTTSLC6A2SLC6A4SLC6A3
SCHEMBL29539584 0.71 KDM4E (0.56) ALDH1A1HTTSLC6A2SLC6A4SLC6A3
SCHEMBL18984732 0.71 KDM4E (0.56) ALDH1A1HTTSLC6A2SLC6A4SLC6A3
SCHEMBL11543918 0.71 SLC6A2 (0.47) ALDH1A1HTTSLC6A2SLC6A4SLC6A3
SCHEMBL314481 0.70 KMT2A (0.39) ALDH1A1HTTLMNAKMT2ARAB9A
SCHEMBL1436765 0.70 HPGD (0.59) ALDH1A1HTTSLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6458813-B1 2-CYCLOHEXYLOXY-5-(2-CHLOROPHENYLCARBONYLAMINO)PYRIDINE, FOR EXAMPLE; TREATING INFLAMMATION, PAIN, DIABETES, CANCER AMGEN INC. 2002-10-01 US disclosed